Latest Prenatal diagnosis Stories
Prenatal screening for Down syndrome (DS) is still in need of improvement. Perinatal medicine experts have worked hard to find new biomarkers for screening of DS. Dr. Shi he Shao and his co-investigators, from Jiangsu University and Changzhou Woman and Children Health Hospital, report in the May 2012 issue of Experimental Biology and Medicine that they have successfully identified twenty-nine differentially expressed proteins in maternal serum from pregnancies carrying DS fetuses with...
Scientists have successfully sequenced the genome of a fetus after taking a blood sample from a woman who was 18 weeks pregnant, and a swab of saliva from the father -- a move that could play a significant role in the screening of rare disorders before the child is even born. The research, published in the journal Science Translational Medicine, is not the first study to have shown a fetal genome can be glimpsed with a sample of the mother’s blood, but does offer a more accurate picture...
--Nurses from The Children's Hospital of Philadelphia Review Dramatic Advances, Describe Best Care Practices-- PHILADELPHIA, June 6, 2012 /PRNewswire-USNewswire/ -- Maternal-fetal care is entering a new era. Highly sophisticated surgical teams now repair spina bifida and other birth defects in the womb, place fetal shunts to treat life-threatening congenital conditions, and perform minimally invasive procedures in the mother's uterus to treat complications in fetal twins. These...
MOUNTAIN VIEW, Calif., June 5, 2012 /PRNewswire/ -- Prenatal testing is an available choice for pregnant women around the world to obtain information at their discretion about the fetus they are carrying. Women may choose to detect chromosome abnormalities in the fetus. For example, mothers-to-be are often told by their OBGYNs about the increased risk of chromosomal abnormality with advanced maternal age. In the United States, the trend of increasing maternal age for women may...
SAN JOSE, Calif., June 4, 2012 /PRNewswire/ -- Ariosa Diagnostics, Inc., a molecular diagnostics company, announced the publication of its NICE (Non-Invasive Chromosomal Evaluation) Study, an international multicenter prospective, cohort study of more than 4,000 pregnant women at gestational age 10 weeks or later from 50 clinical sites. The study evaluated Harmony Prenatal Test's performance in detecting fetal Trisomy 21 and 18, which cause Down syndrome and Edwards...
REDWOOD CITY, Calif., May 31, 2012 /PRNewswire/ -- Verinata Health, Inc., a privately-held company dedicated to maternal and fetal health, today announced that physicians across the country are now using the verifi(TM) prenatal test. In addition, the company will be presenting two key studies demonstrating the company's proprietary method to detect chromosomal abnormalities across the entire genome at the 16th International Conference on Prenatal Diagnosis and...
SAN JOSE, Calif., May 29, 2012 /PRNewswire/ -- Ariosa Diagnostics, Inc., a molecular diagnostics company, today announced it will be presenting two studies and also exhibiting as a meeting sponsor at the upcoming ISPD 16th International Conference on Prenatal Diagnosis and Therapy in Miami Beach, Fla. (Logo: http://photos.prnewswire.com/prnh/20120326/NY75864LOGO ) The first study will be a poster presentation titled, "Analysis of Maternal Age, Gestational Age and Aneuploidy on...
SAN JOSE, Calif., May 23, 2012 /PRNewswire/ -- Ariosa Diagnostics, a molecular diagnostics company, announced today the publication of a study that provides more information on the factors which may influence the amount of fetal DNA found in maternal blood. The study was led by Professor Kypros Nicolaides, MD, of Harris Birthright Research Centre for Fetal Medicine at King's College Hospital in the United Kingdom. (Logo: http://photos.prnewswire.com/prnh/20120326/NY75864LOGO ) The...
SAN DIEGO, May 18, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced that a new publication from the large Women & Infants multi-center clinical study on the Sequenom Center for Molecular Medicine's (Sequenom CMM) MaterniT21 PLUS laboratory-developed test (LDT) has been published online in the peer-reviewed journal, Prenatal Diagnosis. Along with this week's publication, the Company...
SAN JOSE, Calif., May 7, 2012 /PRNewswire/ -- Ariosa Diagnostics, a molecular diagnostics company, today announced that the Harmony(TM) Prenatal Test will be available in the United States and Canada through Laboratory Corporation of America® Holdings (LabCorp®) and Integrated Genetics, a member of LabCorp's Specialty Testing Group. Harmony represents an innovative non-invasive test for detection of common fetal trisomies utilizing a directed approach to analyze cell-free DNA...
